Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Projected Valuation Of The Calcium Channel Blocker Market In The Coming Years?

The market size for calcium channel blockers has experienced robust growth in the last few years. It’s projected to increase from $15.56 billion in 2024 to $16.46 billion in 2025, equating to a compound annual growth rate (CAGR) of 5.8%. Factors such as heightened occurrences of cardiovascular diseases, an aging demographic, advancements in medical studies, evolving lifestyles, and a rise in awareness have contributed towards growth in the historical period.

The market for calcium channel blockers is anticipated to experience robust expansion in the forthcoming years. A rise to “$21.59 billion by 2029 with a compound annual growth rate (CAGR) of 7.0%” is projected. Factors contributing to this growth during the forecast period include an increasing worldwide prevalence of cardiovascular diseases, advances in personalized medicine, improved healthcare accessibility, expansion of usage guidelines, regulatory approvals, and market expansion. Key trends for the forecast period include market expansion, technological innovation, regulatory changes, competitive assessments, patient preferences, and increased awareness.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9428&type=smp

What Growth-Enabling Forces Are Impacting The Calcium Channel Blocker Market?

The rise in cardiovascular disease incidences is predicted to propel the calcium channel blocker market’s expansion in the future. Cardiovascular disease encompasses any health issue involving the heart or blood vessels. Calcium channel blockers (CCBs) are medications used to reduce the probability of heart failure and stroke. As such, the escalating prevalence of cardiovascular diseases is influencing an increased demand for these calcium channel blockers. For example, a report published by the American College of Cardiology in August 2022 predicts that all four cardiovascular risk factors will see a significant rise between 2025 and 2060 in the United States. Diabetes is expected to see the highest percentage increase, at 39.3% or 55 million individuals, followed by dyslipidemia (27.6% to 126 million), hypertension (25.1% to 162 million), and obesity (18.3% to 126 million). The report also noted the largest forecasted surges in cardiovascular disease rates are for stroke (33.8% to 15 million) and heart failure (33.4% to 13 million), followed by ischemic heart disease (30.7% to 29 million) and heart attack (16.9% to 16 million). Consequently, the growth of the calcium channel blocker market is propelled by the increasing prevalence of cardiovascular diseases.

Which Segments Define The Structure Of The Calcium Channel Blocker Market?

The calcium channel blocker market covered in this report is segmented –

1) By Drug Class: Dihydropyridine, Benzothiazepine, Phenylalkylamine, Other Drug Classes

2) By Disease Indications: Hypertension, Chest Pain, Arrhythmias

3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Dihydropyridine: Amlodipine, Nifedipine, Felodipine, Nicardipine, Isradipine

2) By Benzodiazepine: Diazepam

3) By Phenylalkylamine: Verapamil

4) By Other Drug Classes: Bepridil, Lercanidipine, Cilnidipine

What Strategic Shifts And Innovations Are Influencing The Calcium Channel Blocker Market?

A significant trend emerging in the calcium channel blocker market is product innovation. To maintain their stronghold in the market, leading firms are investing in the creation of novel products. For instance, in June 2022, CMP Pharma, a pharmaceutical manufacturer based in the US, rolled out Norliqva. This product is the first and only oral liquid variant of the besylate salt of amlodipine, which is a long-lasting calcium channel blocker. What sets Norliqva apart is its utility as a liquid amlodipine solution that can be used to manage hypertension in people aged 6 years and above. This innovative product eliminates the challenges and inconsistencies associated with crushing or synthesizing amlodipine tablets, assuring consistent dosages and bioequivalence. The target demographic for Norliqva includes patients who need amlodipine but struggle with swallowing or are incapable of doing so.

Who Are The Global Leaders Steering The Calcium Channel Blocker Market Forward?

Major companies operating in the calcium channel blocker market include Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bausch Health Companies Inc., Lupin Pharmaceuticals Inc., Cadila Healthcare Limited, Covis Pharma BV, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals LLC, Sofgen Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Knoll Healthcare Private Limited, Sanofi S.A., Clearsynth Labs Ltd., Searle LLC, Bayer AG, AstraZeneca plc, Wyeth-Ayerst Lederle Inc., GlaxoSmithKline Plc., AbbVie Inc., Silvergate Pharmaceuticals Inc., Exela Pharma Sciences LLC, Arbor Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/calcium-channel-blocker-global-market-report

What Regional Factors Are Accelerating Growth In The Calcium Channel Blocker Market?

North America was the largest region in the calcium channel blocker market in 2024. The regions covered in the calcium channel blocker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=9428&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model